Q1 2020 Results Slides

Issue link: https://liminalbiosciences.com/resources/i/1247103

Contents of this Issue


Page 1 of 11

© 2020 Liminal BioSciences Inc. This presentation contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, statements with respect to the timing of any planned Biologics License Application resubmission for Ryplazim ® plasminogen (human) or Ryplazim ® , the development of R&D programs, the timing of initiation of clinical trials, the exploration of potential alternatives for the future commercialization of Ryplazim ® , if approved, including through a third-party marketing collaboration, and the potential commercial launch of Ryplazim ® , if approved, and the impact of COVID-19 on our business. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Liminal BioSciences' ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Liminal BioSciences' to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the Company's U.S. Securities and Exchange Commission and Canadian Securities Commission filings and reports, including in the Annual Report on Form 20-F for the year ended December 31, 2019, the 6-K containing our results for the quarter ended March 31, 2020 and future filings and reports by the Company, from time to time. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. Copyright notice The information contained in this presentation (including names, images, logos and descriptions portraying Liminal BioSciences' products and/or services) is the property of Liminal BioSciences Inc., of its divisions and / or of its subsidiaries ("Liminal") and is protected by copyright, patent and trademark law and / or other intellectual property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including printing and photocopying, or by any information storage or retrieval system without prior permission in writing from Liminal. Disclaimer Liminal BioSciences reserves the right to make improvements, corrections and/or changes to this presentation at any time. Safe Harbour 2

Articles in this issue

view archives of Webcasts - Q1 2020 Results Slides